摘要
目的研究芪苈强心胶囊联合新四联方案治疗心力衰竭患者的临床效果。方法选取2021年11月至2022年12月九江市第一人民医院收治的90例心力衰竭患者作为研究对象,按照随机数字表法分为对照组(45例)和研究组(45例)。对照组采用血管紧张素受体脑啡肽酶抑制剂(ARNI)/血管紧张素转换酶抑制剂(ACEI)/血管紧张素Ⅱ受体阻滞剂(ARB)+β受体阻滞剂+醛固酮受体拮抗剂(MRA)等常规方案治疗,研究组于对照组的基础上联合芪苈强心胶囊和曲美他嗪进行治疗。比较两组患者的治疗效果、临床指标及肾功能。结果研究组的中医证候积分低于对照组,研究组的中医证候积分治疗效果优于对照组,差异有统计学意义(P<0.05);研究组的心功能等级治疗总有效率高于对照组,差异有统计学意义(P<0.05);研究组血清N端脑钠肽前体(NT-proBNP)、B型钠尿肽(BNP)低于对照组,左室射血分数(LVEF)、6 min步行距离(6MWT)高于对照组,差异有统计学意义(P<0.05);研究组血尿素氮(BUN)、血肌酐(SCr)水平低于对照组,肾小球滤过率(eGFR)水平高于对照组,差异有统计学意义(P<0.05)。结论芪苈强心胶囊联合新四联方案治疗心力衰竭有显著效果,可积极改善患者临床症状及心肾功能,有助于患者提高运动耐量,值得临床推广。
Objective To study the clinical effect of Qili Qiangxin Capsules combined with new quadruple regimen in the treatment of patients with heart failure.Methods A total of 90 patients with heart failure admitted to Jiujiang NO.1 People's Hospital from November 2021 to December 2022 were selected as the study objects,and they were divided into control group(45 cases)and study group(45 cases)according to random number table method.The control group was treated with angiotensin receptor-neprilysin inhibitor(ARNI)/angiotension converting enzyme inhibitor(ACEI)/angiotonin receptor blocker(ARB)+β-blocker+angiotonin receptor blocker(MRA)and other conventional regimens,while the study group was treated with Qili Qiangxin Capsules and Trimetazidine on the basis of the control group.The therapeutic effect,clinical indexes and renal function of the two groups were compared.Results The traditional Chinese medicine syndrome score of the study group was lower than that of the control group,and the therapeutic effect of traditional Chinese medicine syndrome score of the study group was better than that of the control group,the differences were statistically significant(P<0.05).The total effective rate of cardiac function grade treatment in study group was higher than that in control group,the difference was statistically significant(P<0.05).The serum N-terminal pro-brain natriuretic peptide(NT-proBNP)and brain natriuretic peptide(BNP)of the study group were lower than those of the control group,and the left ventricular ejection fraction(LVEF)and six-minute walking test(6MWT)of the study group were higher than those of the control group,with statistical significances(P<0.05).Blood urea nitrogen(BUN)and serum creatinine(SCr)levels in study group were lower than those in control group,and estimated glomerular filtration rate(eGFR)level was higher than that in control group,with statistical significances(P<0.05).Conclusion Qili Qiangxin Capsules combined with new quadruple regimen has a significant effect on the treatment of heart failure,which can actively improve the clinical symptoms and cardiac and renal function of patients,help patients to improve exercise tolerance,and is worthy of clinical promotion.
作者
柳万千
廖然
LIU Wanqian;LIAO Ran(Department of Cardiology,Jiujiang NO.1 People's Hospital,Jiangxi Province,Jiujiang332000,China)
出处
《中国当代医药》
2025年第6期40-44,共5页
China Modern Medicine
基金
江西省中医药管理局科技计划项目(2023B0569)。
关键词
心力衰竭
四联方案
芪苈强心胶囊
曲美他嗪
心功能
肾功能
Heart failure
Quadruple regimen
Qili Qiangxin Capsules
Trimetazidine
Heart function
Renal function
